City Therapeutics
Filed with the SEC on · accession 0001104659-26-124775
CTY filed a 8-K (current report) with the SEC on Nov 10, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
City Therapeutics announced that the first participant has been dosed in a Phase 1 clinical trial of CITY-RBP4 for the treatment of Stargardt disease.
✦ Ask GOAX AI about this filing — what it means for CTY, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for CTY?
Click hereCTY filed a 8-K (SEC filing). City Therapeutics announced that the first participant has been dosed in a Phase 1 clinical trial of CITY-RBP4 for the treatment of Stargardt disease.
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Get alerts when CTY files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days